Medical management of brain tumors and the sequelae of treatment
Authors:
- 30 October 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (4) , 488-504
Abstract
Patients with malignant brain tumors are prone to complications that negatively impact their quality of life and sometimes their overall survival as well. Tumors may directly provoke seizures, hypercoagulable states with resultant venous thromboembolism, and mood and cognitive disorders. Antitumor treatments and supportive therapies also produce side effects. In this review, we discuss major aspects of supportive care for patients with malignant brain tumors, with particular attention to management of seizures, venous thromboembolism, corticosteroids and their complications, chemotherapy including bevacizumab, and fatigue, mood, and cognitive dysfunction.Keywords
This publication has 205 references indexed in Scilit:
- New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsEuropean Journal of Cancer, 2012
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective seriesJournal of Neuro-Oncology, 2012
- Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapyJournal of Neuro-Oncology, 2011
- The incidence of gastrointestinal perforations among rheumatoid arthritis patientsArthritis & Rheumatism, 2010
- Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancerJournal of Neuro-Oncology, 2010
- Morphological Characteristics of Brain Tumors Causing SeizuresArchives of Neurology, 2010
- The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBritish Journal of Cancer, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005